DNMT3A mutations in polycythemia vera (PV) patients were heterogenous and not enriched in interferon-alpha (IFN)-treated patients. DNMT3A mutations had no detectable impact on hematologic response, molecular response or survival outcomes.

Subjects:
Myeloid Neoplasia
This content is only available as a PDF.
Copyright © 2025 American Society of Hematology
2025

Article PDF first page preview

First page of DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera
You do not currently have access to this content.
Sign in via your Institution